State Board of Administration of Florida Retirement System Has $4.87 Million Holdings in Kite Pharma Inc (KITE)

State Board of Administration of Florida Retirement System raised its position in shares of Kite Pharma Inc (NASDAQ:KITE) by 12.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,107 shares of the biopharmaceutical company’s stock after buying an additional 2,980 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Kite Pharma were worth $4,874,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Teacher Retirement System of Texas boosted its position in Kite Pharma by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 3,651 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 52 shares during the period. Aperio Group LLC boosted its position in Kite Pharma by 7.6% during the 3rd quarter. Aperio Group LLC now owns 6,755 shares of the biopharmaceutical company’s stock valued at $1,215,000 after buying an additional 476 shares during the period. Ameritas Investment Partners Inc. boosted its position in Kite Pharma by 17.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,292 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 638 shares during the period. California State Teachers Retirement System boosted its position in Kite Pharma by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 86,578 shares of the biopharmaceutical company’s stock valued at $8,976,000 after buying an additional 709 shares during the period. Finally, Amalgamated Bank boosted its position in Kite Pharma by 17.8% during the 2nd quarter. Amalgamated Bank now owns 6,045 shares of the biopharmaceutical company’s stock valued at $627,000 after buying an additional 914 shares during the period. 87.72% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/15/state-board-of-administration-of-florida-retirement-system-has-4-87-million-holdings-in-kite-pharma-inc-kite.html.

In other Kite Pharma news, Chairman Arie Belldegrun sold 26,347 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $4,733,502.02. Following the completion of the sale, the chairman now directly owns 135,507 shares in the company, valued at approximately $24,345,187.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Cynthia M. Butitta sold 4,228 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $759,602.48. Following the sale, the chief operating officer now owns 125,795 shares of the company’s stock, valued at $22,600,329.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,936 shares of company stock valued at $8,791,842. 14.00% of the stock is owned by company insiders.

Several equities research analysts have weighed in on the stock. SunTrust Banks, Inc. cut shares of Kite Pharma from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Wedbush raised shares of Kite Pharma from an “underperform” rating to a “neutral” rating in a research report on Tuesday, August 29th. BTIG Research cut shares of Kite Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, August 28th. Jefferies Group LLC reissued a “buy” rating and set a $135.00 price target (up previously from $121.00) on shares of Kite Pharma in a research report on Wednesday, August 9th. Finally, Canaccord Genuity set a $120.00 price target on shares of Kite Pharma and gave the company a “buy” rating in a research report on Wednesday, August 9th. Thirteen equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $94.68.

Kite Pharma Inc (KITE) opened at $179.99 on Wednesday. Kite Pharma Inc has a 12 month low of $39.82 and a 12 month high of $179.99.

Kite Pharma Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma Inc (NASDAQ:KITE).

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply